just a FYI (and for parking), these guys/gals keep taking shots at del-1....
Tuesday March 21, 12:31 pm Eastern Time
Company Press Release
Endovasc Applauds Result of Generxs Non-Surgical By-Pass Trials
Adds That Endovasc's Own Nicotine Therapy Proved Twice as Potent
MONTGOMERY, TX.--(BUSINESS WIRE)--March 21, 2000--Dr. David P. Summers, Chairman and CEO of Endovasc
Ltd., Inc. (ENDV:OTC) today stated that the announcement that Fibrolast Growth Factor-4 (FGF-4) gene therapy used in
clinical trials sponsored by Collateral Therapeutics Inc. produced positive results was great news for the field of angiogenesis,
the creation of new blood vessels to circumvent blocked arteries to the heart.
But, he added, recent work done at Stanford University, which has been licensed by Endovasc, showed that FGF-4 did slightly
better than the controls. The study also demonstrated that Endovasc's own growth factor nicotine applied in small harmless
doses - was twice as powerful as FGF in animal studies.
``The study conducted at Stanford University by Dr. Christian Heeschen and co-workers was a well-characterized one that
measured quantifiable fibrovascular growth, capillary density and blood flow measured by magnetic resonance imaging (MRI),'
Dr. Summers said. ``Unequivocally, the work demonstrated that low-dose nicotine was two-fold more effective not only over
FGF-4 but also another promising growth factor, DEL-1. We are also pleased that the Stanford work, just announced at the
March 13th conference of the American College of Cardiology, was honored by that important organization as one of the
outstanding studies of the national meeting of cardiologists.'
Dr. Summers pointed out that non-surgical angiognesis may not only benefit the six million angina patients in this nation by
creating new blood vessels to circumvent blocked arteries, but could reduce the need for the 500,000 coronary by-pass
operations and the 800,000 angioplasties performed each year in North America, let alone worldwide.``
Endovasc estimates that the market for a successful angiogenesis product would surpass $2 billion by 2005.
Endovasc Ltd., Inc. (ENDV:OTC), is a biopharmaceutical company specializing in products covered by patents to improve
circulation in limbs and heart.
The foregoing statements are made under the ``Safe Harbor' Private Securities Litigation Reform Act of 1995 and may contain
forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release.
Contact:
For Endovasc Ltd., Inc.
The Dilenschneider Group
Matt Swetonic
Phone: 212/922-0900
Fax: 212/922-0971
e-mail: Mswetonic@DGI-NYC.COM
or
Endovasc Ltd., Inc.
Barbara Richardson
Phone: 936/448-2222
Fax: 936/582-2250
e-mail: bjr@endovasc.com |
